FindTrial
Sign In

Median effective dose of alfentanil combined with propofol inhibiting responses to laryngeal mask airway insertion in children

Median effective dose of alfentanil combined with propofol inhibiting responses to laryngeal mask airway insertion in children

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300070105
Enrollment
Unknown
Registered
2023-04-03
Start date
2023-04-03
Completion date
Unknown
Last updated
2023-05-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

facial skin pigmented

Interventions

case senes:Alfentanil combined with propofol

Sponsors

Hangzhou Third People’s Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
6 Years to 14 Years

Inclusion criteria

Inclusion criteria: facial skin pigmented nevus resection children, ASA physical status ?, aged 6-14years, BMI 18-24 kg/m2.

Exclusion criteria

Exclusion criteria: Upper respiratory tract infection within 2 weeks,asthma history

Design outcomes

Primary

MeasureTime frame
LMA insertion responses;swallow;bucking;body movement;Half effective dose;—

Countries

CHINA

Contacts

Public ContactWangbo

Hangzhou Third People’s Hospital

qiubajia@163.com15068180821

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026